Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

Sci Rep. 2020 Nov 11;10(1):19870. doi: 10.1038/s41598-020-76679-x.

Authors

Sabina Luszczak¹, Benjamin S Simpson¹, Urszula Stopka-Farooqui¹, Vignesh Krishna Sathyadevan¹, Lina M Carmona Echeverria¹, Christopher Kumar¹, Helena Costa², Aiman Haider², Alex Freeman², Charles Jameson², Marzena Ratynska², Imen Ben-Salha², Ashwin Sridhar³, Greg Shaw³, John D Kelly³, Hayley Pye¹, Kathy A Gately⁴, Hayley C Whitaker¹, Susan Heavey⁵

Affiliations

¹ Molecular Diagnostics and Therapeutics Group, University College London, London, UK.
² 2Research Department of Pathology, University College London, London, UK.
³ Department of Uro‑Oncology, UCLH NHS Foundation Trust, London, UK.
⁴ Trinity Translational Medicine Institute, St. James's Hospital Dublin, Dublin 8, Ireland.
⁵ Molecular Diagnostics and Therapeutics Group, University College London, London, UK. s.heavey@ucl.ac.uk.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Publication types

Published Erratum